All In Biotech

Drug Trial Radar · NCT05629962

SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

Last checked: Nov 20, 2026Latest source record: Jun 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,285 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,285

Actual

Start

Nov 25, 2022

Primary completion

Apr 25, 2024

Study completion May 30, 2024

Sponsor

Lead sponsor
Atea Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Nov 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in adults with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible subjects will be randomly assigned (by chance) to receive BEM or matching placebo orally for 5 days. Co-administration of locally available standard of care (SOC) is allowed. The total duration of the study is 60 days.

Conditions

  • Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)
  • COVID-19

Interventions

  • Bemnifosbuvir (BEM)Drug

    BEM tablets administered orally every 12 hours (twice a day) for a total of 5 days

  • PlaceboDrug

    Placebo tablets administered orally every 12 hours (twice a day) for a total of 5 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Hospitalized for Any Cause or Died Due to Any CauseTime frame: Day 1 through Day 29

Locations

263 sites in 19 countries. Site status is shown where the registry gives one.

  • Atea Study Site

    Kingman, Arizona

  • Atea Study Site

    Prescott, Arizona

  • Atea Study Site

    Surprise, Arizona

  • Atea Study Site

    Tucson, Arizona

  • Atea Study Site

    Canoga Park, California

  • Atea Study Site

    Fullerton, California

  • Atea Study Site

    Inglewood, California

  • Atea Study Site

    La Palma, California

  • Atea Study Site

    Long Beach, California

  • Atea Study Site

    Long Beach, California

  • Atea Study Site

    Los Angeles, California

  • Atea Study Site

    Sacramento, California

  • Atea Study Site

    San Diego, California

  • Atea Study Site

    Coral Gables, Florida

  • Atea Study Site

    Cutler Bay, Florida

  • Atea Study Site

    Doral, Florida

  • Atea Study Site

    Hialeah, Florida

  • Atea Study Site

    Miami, Florida

  • Atea Study Site

    Miami, Florida

  • Atea Study Site

    Miami, Florida

  • Atea Study Site

    Miami, Florida

  • Atea Study Site

    Miami, Florida

  • Atea Study Site

    Miami, Florida

  • Atea Study Site

    Miami, Florida

  • Atea Study Site

    Miami Gardens, Florida

  • Atea Study Site

    North Miami Beach, Florida

  • Atea Study Site

    North Miami Beach, Florida

  • Atea Study Site

    Pembroke Pines, Florida

  • Atea Study Site

    Pompano Beach, Florida

  • Atea Study Site

    Tampa, Florida

  • Atea Study Site

    Tampa, Florida

  • Atea Study Site

    Tampa, Florida

  • Atea Study Site

    Tampa, Florida

  • Atea Study Site

    The Villages, Florida

  • Atea Study Site

    West Miami, Florida

  • Atea Study Site

    West Palm Beach, Florida

  • Atea Study Site

    Eatonton, Georgia

  • Atea Study Site

    Orland Park, Illinois

  • Atea Study Site

    La Vista, Nebraska

  • Atea Study Site

    The Bronx, New York

Showing 40 of 263 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.